Adaptive Platform Treatment Trial for Outpatients with COVID-19 (ACTIV-2)
Outpatient Treatment for COVID-19 (ACTIV-2)
Sponsor: National Institute of Allergy and Infectious Diseases NIAID
Enrolling: Male and Female Patients
Study Length: 18 Months
Clinic Visits: 11
IRB Number: AAAT6083
U.S. Govt. ID: NCT04518410
Contact: Bronx Prevention Center: 347-590-7280 / lp2907@cumc.columbia.edu
Additional Study Information: This study enrolls people recently diagnosed with COVID-19, who are not currently in the hospital. The study tests several different investigational medicines to see if they are safe and can help adults with COVID-19 get better, with the goal of quickly determining those that are safe and effective. Help us to rise above COVID-19!
This study is closed
Investigator
Ellen Morrison, MD, MPH
Do You Qualify?
Are you having any symptoms of COVID-19 (i.e., fever, body aches, chills, loss of taste/smell, etc.)? Yes No
Have you been hospitalized for COVID-19? Yes No
Are you pregnant or breastfeeding? If N/A, select No. Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Bronx Prevention Center
lp2907@cumc.columbia.edu
347-590-7280
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE